Cure Today13h
Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC
Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...
FiercePharma9d
ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
GlobalData on MSN7d
AstraZeneca’s Imfinzi and Imjudo found to extend survival in liver cancer trial
Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.
Astra’s Blockbuster Drug Scores Major Win in Bladder Cancer
AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the ...
Cure Today8d
Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC
Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...
AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission
The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...
FiercePharma11h
AstraZeneca shows ‘What Science Can Do’ for patients’ lives in new video series
The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...
AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...